HER2/neu (human epidermal growth factor receptor 2) alterations represent a predicitive biomarker and a promising therapeutic target in up to 10% of cholangiocarcinomas and up to 20% of gallbladder carcinomas (ESMO Guideline 2023). The gene discussed is ERBB2; the disease is gallbladder carcinoma.